Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production

Thomas Kukar, Michael Paul Murphy, Jason L. Eriksen, Sarah A. Sagi, Sascha Weggen, Tawnya E. Smith, Thomas Ladd, Murad A. Khan, Rajashaker Kache, Jenny Beard, Mark Dodson, Sami Merit, Victor V. Ozols, Panagiotis Z Anastasiadis, Pritam Das, Abdul Fauq, Edward H. Koo, Todd E. Golde

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Increased Aβ42 production has been linked to the development of Alzheimer disease. We now identify a number of compounds that raise Aβ42. Among the more potent Aβ42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised Aβ42, including multiple COX-2-selective derivatives of two Aβ42-lowering NSAIDs. Compounds devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised Aβ42. These compounds seem to target the γ-secretase complex, increasing γ-secretase-catalyzed production of Aβ42 in vitro. Short-term in vivo studies show that two Aβ42-raising compounds increase Aβ42 levels in the brains of mice. The elevations in Aβ42 by these compounds are comparable to the increases in Aβ42 induced by Alzheimer disease-causing mutations in the genes encoding amyloid β protein precursor and presenilins, raising the possibility that exogenous compounds or naturally occurring isoprenoids might increase Aβ42 production in humans.

Original languageEnglish (US)
Pages (from-to)545-550
Number of pages6
JournalNature Medicine
Volume11
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Non-Steroidal Anti-Inflammatory Agents
Amyloid Precursor Protein Secretases
Alzheimer Disease
Celecoxib
Terpenes
Mutation
Presenilins
Fenofibrate
Gene encoding
Amyloid beta-Protein Precursor
Brain
Derivatives
Genes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Kukar, T., Murphy, M. P., Eriksen, J. L., Sagi, S. A., Weggen, S., Smith, T. E., ... Golde, T. E. (2005). Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. Nature Medicine, 11(5), 545-550. https://doi.org/10.1038/nm1235

Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. / Kukar, Thomas; Murphy, Michael Paul; Eriksen, Jason L.; Sagi, Sarah A.; Weggen, Sascha; Smith, Tawnya E.; Ladd, Thomas; Khan, Murad A.; Kache, Rajashaker; Beard, Jenny; Dodson, Mark; Merit, Sami; Ozols, Victor V.; Anastasiadis, Panagiotis Z; Das, Pritam; Fauq, Abdul; Koo, Edward H.; Golde, Todd E.

In: Nature Medicine, Vol. 11, No. 5, 05.2005, p. 545-550.

Research output: Contribution to journalArticle

Kukar, T, Murphy, MP, Eriksen, JL, Sagi, SA, Weggen, S, Smith, TE, Ladd, T, Khan, MA, Kache, R, Beard, J, Dodson, M, Merit, S, Ozols, VV, Anastasiadis, PZ, Das, P, Fauq, A, Koo, EH & Golde, TE 2005, 'Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production', Nature Medicine, vol. 11, no. 5, pp. 545-550. https://doi.org/10.1038/nm1235
Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. Nature Medicine. 2005 May;11(5):545-550. https://doi.org/10.1038/nm1235
Kukar, Thomas ; Murphy, Michael Paul ; Eriksen, Jason L. ; Sagi, Sarah A. ; Weggen, Sascha ; Smith, Tawnya E. ; Ladd, Thomas ; Khan, Murad A. ; Kache, Rajashaker ; Beard, Jenny ; Dodson, Mark ; Merit, Sami ; Ozols, Victor V. ; Anastasiadis, Panagiotis Z ; Das, Pritam ; Fauq, Abdul ; Koo, Edward H. ; Golde, Todd E. / Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. In: Nature Medicine. 2005 ; Vol. 11, No. 5. pp. 545-550.
@article{4460cc2efd0843d99cba02e4fd4a5eee,
title = "Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production",
abstract = "Increased Aβ42 production has been linked to the development of Alzheimer disease. We now identify a number of compounds that raise Aβ42. Among the more potent Aβ42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised Aβ42, including multiple COX-2-selective derivatives of two Aβ42-lowering NSAIDs. Compounds devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised Aβ42. These compounds seem to target the γ-secretase complex, increasing γ-secretase-catalyzed production of Aβ42 in vitro. Short-term in vivo studies show that two Aβ42-raising compounds increase Aβ42 levels in the brains of mice. The elevations in Aβ42 by these compounds are comparable to the increases in Aβ42 induced by Alzheimer disease-causing mutations in the genes encoding amyloid β protein precursor and presenilins, raising the possibility that exogenous compounds or naturally occurring isoprenoids might increase Aβ42 production in humans.",
author = "Thomas Kukar and Murphy, {Michael Paul} and Eriksen, {Jason L.} and Sagi, {Sarah A.} and Sascha Weggen and Smith, {Tawnya E.} and Thomas Ladd and Khan, {Murad A.} and Rajashaker Kache and Jenny Beard and Mark Dodson and Sami Merit and Ozols, {Victor V.} and Anastasiadis, {Panagiotis Z} and Pritam Das and Abdul Fauq and Koo, {Edward H.} and Golde, {Todd E.}",
year = "2005",
month = "5",
doi = "10.1038/nm1235",
language = "English (US)",
volume = "11",
pages = "545--550",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production

AU - Kukar, Thomas

AU - Murphy, Michael Paul

AU - Eriksen, Jason L.

AU - Sagi, Sarah A.

AU - Weggen, Sascha

AU - Smith, Tawnya E.

AU - Ladd, Thomas

AU - Khan, Murad A.

AU - Kache, Rajashaker

AU - Beard, Jenny

AU - Dodson, Mark

AU - Merit, Sami

AU - Ozols, Victor V.

AU - Anastasiadis, Panagiotis Z

AU - Das, Pritam

AU - Fauq, Abdul

AU - Koo, Edward H.

AU - Golde, Todd E.

PY - 2005/5

Y1 - 2005/5

N2 - Increased Aβ42 production has been linked to the development of Alzheimer disease. We now identify a number of compounds that raise Aβ42. Among the more potent Aβ42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised Aβ42, including multiple COX-2-selective derivatives of two Aβ42-lowering NSAIDs. Compounds devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised Aβ42. These compounds seem to target the γ-secretase complex, increasing γ-secretase-catalyzed production of Aβ42 in vitro. Short-term in vivo studies show that two Aβ42-raising compounds increase Aβ42 levels in the brains of mice. The elevations in Aβ42 by these compounds are comparable to the increases in Aβ42 induced by Alzheimer disease-causing mutations in the genes encoding amyloid β protein precursor and presenilins, raising the possibility that exogenous compounds or naturally occurring isoprenoids might increase Aβ42 production in humans.

AB - Increased Aβ42 production has been linked to the development of Alzheimer disease. We now identify a number of compounds that raise Aβ42. Among the more potent Aβ42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Many COX-2-selective NSAIDs tested raised Aβ42, including multiple COX-2-selective derivatives of two Aβ42-lowering NSAIDs. Compounds devoid of COX activity and the endogenous isoprenoids FPP and GGPP also raised Aβ42. These compounds seem to target the γ-secretase complex, increasing γ-secretase-catalyzed production of Aβ42 in vitro. Short-term in vivo studies show that two Aβ42-raising compounds increase Aβ42 levels in the brains of mice. The elevations in Aβ42 by these compounds are comparable to the increases in Aβ42 induced by Alzheimer disease-causing mutations in the genes encoding amyloid β protein precursor and presenilins, raising the possibility that exogenous compounds or naturally occurring isoprenoids might increase Aβ42 production in humans.

UR - http://www.scopus.com/inward/record.url?scp=21044458540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044458540&partnerID=8YFLogxK

U2 - 10.1038/nm1235

DO - 10.1038/nm1235

M3 - Article

VL - 11

SP - 545

EP - 550

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 5

ER -